Longhorn Vaccines and Diagnostics announced today new data from the USDA National Veterinary Services Laboratory validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (PS-MTM), and its potential to inactivate highly consequential livestock and poultry viruses to support safer and more effective diagnostic testing.
AGC Biologics today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg Read More »
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.
Aronora Secures Investment From New York Blood Center Read More »
ReAlta Life Sciences was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
HCA Healthcare’s Johnston-Willis Hospital in Richmond, Virginia, is the first hospital in the United States to provide treatment in a new clinical trial for patients with brain metastases from lung cancer.
BioCT is delighted to announce the appointment of David Scheer as Co-Chair of its Board of Directors.
BioCT appoints David Scheer as Co-Chair of the Board of Directors, welcomes new director Read More »
ValGenesis, Inc. and Brevitas, an independent technology consulting firm, have partnered to introduce the ValGenesis product suite alongside Brevitas’ immense technical expertise in life sciences across the US and Canada.
ValGenesis and Brevitas Announce Strategic Partnership Read More »
Eli Lilly and Company announced that mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease.
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.
